Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,otherCurrentAssets,otherLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,postMarketChangePercent,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,postMarketTime,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,FMTX,616465000.0,47372700,,,-35952000,,-35960000,9867000,-26343000,-36210000,-36210000,,,,,,8000,0,36210000,26343000,258000,,-35960000,-35960000,709788000.0,33771000.0,616465000.0,1225000.0,650236000.0,47000.0,-93370000.0,15025000.0,97834000.0,28557000.0,8347000.0,573868000.0,52996000.0,452894000.0,17075000.0,2927000.0,,,-143368000.0,-1368000.0,-143451000.0,-167000.0,-8972000.0,333000.0,-184855000.0,-41237000.0,183000.0,-500000.0,4600000.0,-83000.0,,545311000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Forma Therapeutics Holdings, In",False,False,NGM,0.0,24.39,1630526402,0.3599987,24.07,24.73,24.07,131205,POST,0,2,24.39,0.0,1.4981219,24.07 - 24.73,24.03,23.5,25.47,12,13,finmb_180567741,"Forma Therapeutics Holdings, Inc.",1630526489,NasdaqGM,USD,309507,213233,3.3499985,0.15922046,21.04 - 56.33,-31.940002,-0.5670158,21.04,56.33,1617107400,1617107400,1617107400,-3.49,-6.9885383,23.59361,0.7963886,0.03375442,27.776304,-3.3863049,-0.12191344,1216536576,15,America/New_York,EDT,-14400000,,,,56.33,21.04,23.59,27.78,309.51k,213.23k,47.37M,,23.27M,8.05%,91.51%,2.79M,11.05,8.71%,5.60%,3.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.02%,-29.95%,,,,-93.37M,-127.3M,-115.95M,,,550.73M,11.64,8.26M,1.34,20.10,,-103.24M,-55.19M,Value,02472,Healthcare,114,9,8,"Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",Watertown,617 679 1970,MA,8,1609372800,1622505600,5,United States,http://www.formatherapeutics.com,86400,7,500 Arsenal Street,Biotechnology,Suite 100
t-1,FMTX,648244000.0,47372700,,,-31778000,,-28588000,7941000,-24866000,-32807000,-32807000,,,,,,-3190000,0,32807000,24866000,1029000,,-28588000,-28588000,705607000.0,32727000.0,648244000.0,1273000.0,680971000.0,47000.0,-57410000.0,12470000.0,282689000.0,31700000.0,1520000.0,654447000.0,12534000.0,350365000.0,15273000.0,4295000.0,1327000.0,1027000.0,-58785000.0,578000.0,-43854000.0,258997000.0,1934000.0,258997000.0,202824000.0,-12319000.0,200000.0,-500000.0,1833000.0,-115000.0,,622747000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Forma Therapeutics Holdings, In",False,False,NGM,0.0,24.39,1630526402,0.3599987,24.07,24.73,24.07,131205,POST,0,2,24.39,0.0,1.4981219,24.07 - 24.73,24.03,23.5,25.47,12,13,finmb_180567741,"Forma Therapeutics Holdings, Inc.",1630526489,NasdaqGM,USD,309507,213233,3.3499985,0.15922046,21.04 - 56.33,-31.940002,-0.5670158,21.04,56.33,1617107400,1617107400,1617107400,-3.49,-6.9885383,23.59361,0.7963886,0.03375442,27.776304,-3.3863049,-0.12191344,1216536576,15,America/New_York,EDT,-14400000,,,,56.33,21.04,23.59,27.78,309.51k,213.23k,47.37M,,23.27M,8.05%,91.51%,2.79M,11.05,8.71%,5.60%,3.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.02%,-29.95%,,,,-93.37M,-127.3M,-115.95M,,,550.73M,11.64,8.26M,1.34,20.10,,-103.24M,-55.19M,Value,02472,Healthcare,114,9,8,"Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",Watertown,617 679 1970,MA,8,1609372800,1622505600,5,United States,http://www.formatherapeutics.com,86400,7,500 Arsenal Street,Biotechnology,Suite 100
t-2,FMTX,415602000.0,47372700,,,-31422000,,-27616000,7460000,-24780000,-32240000,-32240000,,,,,,-3806000,0,32240000,24780000,818000,,-27616000,-27616000,444383000.0,31794000.0,415602000.0,1462000.0,447396000.0,41000.0,-28822000.0,2470000.0,79865000.0,30666000.0,1672000.0,415661000.0,27593000.0,286888000.0,42337000.0,3717000.0,,1128000.0,-265384000.0,27000.0,-265415000.0,-1418000.0,2625000.0,258997000.0,-293107000.0,-26274000.0,249000.0,-500000.0,1743000.0,-31000.0,-1418000.0,384995000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Forma Therapeutics Holdings, In",False,False,NGM,0.0,24.39,1630526402,0.3599987,24.07,24.73,24.07,131205,POST,0,2,24.39,0.0,1.4981219,24.07 - 24.73,24.03,23.5,25.47,12,13,finmb_180567741,"Forma Therapeutics Holdings, Inc.",1630526489,NasdaqGM,USD,309507,213233,3.3499985,0.15922046,21.04 - 56.33,-31.940002,-0.5670158,21.04,56.33,1617107400,1617107400,1617107400,-3.49,-6.9885383,23.59361,0.7963886,0.03375442,27.776304,-3.3863049,-0.12191344,1216536576,15,America/New_York,EDT,-14400000,,,,56.33,21.04,23.59,27.78,309.51k,213.23k,47.37M,,23.27M,8.05%,91.51%,2.79M,11.05,8.71%,5.60%,3.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.02%,-29.95%,,,,-93.37M,-127.3M,-115.95M,,,550.73M,11.64,8.26M,1.34,20.10,,-103.24M,-55.19M,Value,02472,Healthcare,114,9,8,"Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",Watertown,617 679 1970,MA,8,1609372800,1622505600,5,United States,http://www.formatherapeutics.com,86400,7,500 Arsenal Street,Biotechnology,Suite 100
t-3,FMTX,438497000.0,47372700,,,-28678000,,-25440000,6448000,-20511000,-26959000,-26959000,,,,,,-3238000,0,26959000,20511000,-1719000,,-25440000,-27240000,439662000.0,29015000.0,438497000.0,1172000.0,467512000.0,41000.0,-1206000.0,495000.0,374947000.0,24818000.0,1901000.0,455116000.0,10000000.0,39354000.0,37600000.0,3753000.0,,4197000.0,-7209000.0,1748000.0,-7234000.0,295258000.0,172000.0,295267000.0,264618000.0,-23406000.0,284000.0,-9000.0,3146000.0,-25000.0,-1418000.0,430298000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Forma Therapeutics Holdings, In",False,False,NGM,0.0,24.39,1630526402,0.3599987,24.07,24.73,24.07,131205,POST,0,2,24.39,0.0,1.4981219,24.07 - 24.73,24.03,23.5,25.47,12,13,finmb_180567741,"Forma Therapeutics Holdings, Inc.",1630526489,NasdaqGM,USD,309507,213233,3.3499985,0.15922046,21.04 - 56.33,-31.940002,-0.5670158,21.04,56.33,1617107400,1617107400,1617107400,-3.49,-6.9885383,23.59361,0.7963886,0.03375442,27.776304,-3.3863049,-0.12191344,1216536576,15,America/New_York,EDT,-14400000,,,,56.33,21.04,23.59,27.78,309.51k,213.23k,47.37M,,23.27M,8.05%,91.51%,2.79M,11.05,8.71%,5.60%,3.32M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-19.02%,-29.95%,,,,-93.37M,-127.3M,-115.95M,,,550.73M,11.64,8.26M,1.34,20.10,,-103.24M,-55.19M,Value,02472,Healthcare,114,9,8,"Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.",Watertown,617 679 1970,MA,8,1609372800,1622505600,5,United States,http://www.formatherapeutics.com,86400,7,500 Arsenal Street,Biotechnology,Suite 100
